

D E A R B O R N

P A R T N E R S

On February 4, 2019 Gilead Sciences, Inc. (GILD) announced that its Board of Directors approved an increase in its quarterly cash dividend per share to \$0.63 (\$2.52 annually) from \$0.57 (\$2.28 annually). This is a 10.5% increase from the dividend the Company paid a year earlier. The dividend is payable on March 28, 2019 to shareholders of record March 15, 2019.

From the fourth quarter 2018 earnings call by Robin L. Washington, Executive Vice President & Chief Financial Officer: “Earlier today, we announced an 11% increase in our quarterly dividend from \$0.57 to \$0.63 per share, which will become effective in the first quarter of 2019. This represents the fourth consecutive year of double-digit increases to the dividend and underscores our confidence in the strength of the business and future cash flows. In 2019, our capital allocation priorities will remain the same with a focus on M&A and partnership to augment our pipeline followed by dividends and share repurchases.”

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Sciences is in the Health Care sector of our Dearborn Partners Core Rising Dividend separately managed account (SMA) portfolio. So far this year, 7 of the 49 companies in this portfolio have announced dividend increases averaging about 7.8% more than those companies paid as dividends a year earlier.

Thank you for your interest in our Dearborn Partners Rising Dividend Strategy.

This dividend increase announcement is not a complete description of, nor a recommendation to invest in, any investment strategy (the “Strategy”) mentioned herein. It is for informational purposes only and does not constitute an offer to sell nor a solicitation to buy, is not a recommendation regarding any securities transaction, nor is it an offer to provide advisory or other services by Dearborn Partners, L.L.C. The information contained in this writing should not be construed as financial or investment advice on any subject matter. Past performance is no guarantee of future results. There is no assurance the Strategy will be profitable, achieve its objectives, be suitable for you, or not incur losses. Some of the information herein has been obtained from third party sources. We believe such information is reliable but we have not in each case verified its accuracy or completeness. Any opinions herein are as of the date of this report and are subject to change without notice. Dividends are not guaranteed and must be authorized by the company’s board of directors. There is no assurance that any Rising Dividend portfolio company will increase its dividend, or not reduce its dividend, or not have a significant decrease in its stock price. Dividend yield is one component of performance and should not be the only consideration for investment. Dearborn Partners L.L.C. is an investment adviser registered under the Investment Advisers Act of 1940, as amended. Registration does not imply a certain level of skill or training.